IMV News and Press, IMV Inc. From 04/04/19

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference , which will be held from April 30 to May 1, 2...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that preclinical research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 demonstrated how the mechanism of action (MOA) of IMV’s proprietary DPX tech...

IMV (NASDAQ: IMV ) announces preliminary data from the phase 2 portion of the DECIDE study in patients with advanced recurrent ovarian cancer. More news on: IMV Inc., Healthcare stocks news, Read more ...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT ...

I have been studying what effect uplisting has on the stock price of individual stocks. My first article concluded that a profit exceeding 25% was available in 65% of stocks that had uplisted during 2015 but that profit evaporated within the first year after uplisting. Only 10% of these same...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019. Details on each conference and p...

IMV (NASDAQ: IMV ): FY GAAP EPS of -C$0.50. More news on: IMV Inc., Earnings news and commentary, , Read more ...

Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq...

IMV Inc. (IMV) (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Canadian bioresearch consortium CQDM has awarded a grant to a collaboration among IMV, Centre de recherche du CHU de Québec-Université Laval, and La Fondation du CHU de Qu&...

The following slide deck was published by IMV Inc. in conjunction with this Read more ...